Home / Deep Research / Pyruvate Dehydrogenase Deficiency

Pyruvate Dehydrogenase Deficiency

Pyruvate Dehydrogenase Deficiency Deep Research Fallback

⚠️ Fallback MONDO:0019169

Pyruvate Dehydrogenase Deficiency Deep Research Fallback

Provider Attempts

  • 2026-05-05T19:39Z: just research-disorder falcon "Pyruvate dehydrogenase deficiency" failed before provider execution because the disorder YAML file had not yet been created.
  • 2026-05-05T19:42Z: direct deep-research-client research with provider falcon produced no output during the bounded 240 second wait and was terminated by timeout.
  • 2026-05-05T19:47Z: direct deep-research-client research with provider openai produced no output during the bounded 180 second wait and was terminated by timeout.
  • 2026-05-05T19:52Z: direct deep-research-client research with provider openscientist produced no output during the bounded 180 second wait and was terminated by timeout.
  • 2026-05-05T20:07Z: direct deep-research-client research with provider perplexity failed immediately with a 401 quota error.

No provider-generated deep-research narrative was available within the bounded runtime. Curation therefore proceeded from regenerated structured Orphanet records, fetched PubMed caches, fetched ClinicalTrials.gov caches, and direct NCBI/ClinicalTrials.gov metadata checks. No references_cache/*.md file was created or edited by hand.

Evidence Scope Used For Curation

  • ORPHA:765 for the disease definition, inheritance, age of onset, prevalence, exact MONDO mapping, broad OMIM subtype mappings, and structured root HPO phenotype rows.
  • ORPHA:79243, ORPHA:255138, ORPHA:79244, ORPHA:2394, ORPHA:255182, and ORPHA:79246 for the six recognized PDH complex subunit/regulatory subtypes, exact subtype MONDO/OMIM cross-references, and disease-causing gene rows.
  • PMID:22896851 for the 371-patient clinical, biochemical, neuroimaging, and natural-history spectrum.
  • PMID:23622387 for diagnostic approach, PDH complex architecture, major subtypes, and sex-linked PDHA1 presentation patterns.
  • PMID:21908116 for the PDH complex glycolysis-to-TCA role, epilepsy mechanism, structural brain-anomaly mechanism, and ketogenic-diet bypass rationale.
  • PMID:28101805 for human clinical ketogenic-diet outcomes in 19 Swedish pediatric patients.
  • PMID:26008863 for thiamine-responsive PDHA1-associated paroxysmal exercise-induced dystonia.
  • PMID:29445841 for E1-alpha folding/assembly defects and impaired PDC activity.
  • PMID:16651305 and PMID:18411236 for dichloroacetate clinical-trial evidence, lactate reduction, lack of broad clinical-outcome improvement, and neuropathy safety signal.
  • PMID:23467562 and PMID:35996497 for phenylbutyrate mechanism, in vitro/model evidence, variant-specific potential responsiveness, and the comparative DCA/phenylbutyrate treatment landscape.
  • clinicaltrials:NCT02616484 for the active-not-recruiting Phase 3 dichloroacetate trial, clinicaltrials:NCT03734263 for the completed Phase 2 phenylbutyrate trial, and clinicaltrials:NCT03056794 for the recruiting natural-history/genetic study.

Curation Conclusions

Pyruvate dehydrogenase deficiency is best represented as a genetically heterogeneous neurometabolic mitochondrial disorder in which defects in PDH complex structural subunits or regulatory phosphatase reduce conversion of pyruvate to acetyl-CoA. The metabolic block links glycolysis to inadequate TCA cycle substrate supply, pyruvate/lactate accumulation, lactic acidosis, and energy failure in the developing brain. Human cohort and review evidence supports neurodevelopmental delay, hypotonia, seizures, corpus-callosum and ventricular abnormalities, Leigh-like neuroimaging, and early mortality in the severe neonatal end of the spectrum. Treatment evidence is strongest for ketogenic diet as a bypass strategy providing acetyl-CoA through fatty-acid oxidation/ketosis; thiamine responsiveness exists in selected PDHA1 variants; dichloroacetate and sodium phenylbutyrate remain targeted pharmacologic or investigational approaches with biochemical rationale and limited or mixed clinical evidence.